Navigation Links
Study lays groundwork for norovirus anti-viral treatments
Date:7/22/2013

ANN ARBOR, Mich. An animal model of the human norovirus created at the University of Michigan Health System lays the groundwork for understanding the biology of the pesky virus and developing antiviral drug treatment.

Well-known as the virus that impacts cruise ship vacations, norovirus leads to misery on land too. The virus spreads quickly from person to person in any closed-in space, such as schools, nursing homes, or day-care centers.

"The first virus in this group was discovered in 1972 following a disease outbreak at a school in Norwalk, Ohio in 1968. Since then research has been underway to culture noroviruses in the laboratory and develop animal models," says lead researcher Christiane Wobus, Ph.D., assistant professor in the Department of Microbiology and Immunology at the University of Michigan Medical School.

An international group of scientists from the U.S. and Germany authored the study published in mBIO, a journal of the American Society of Microbiology.

"Norovirus research has been hampered by the absence of a norovirus cell culture and a genetically manipulable small animal model," Wobus says. "This new model gives us the tool to test potential antiviral compounds and may lay the foundation to culture these viruses in the lab."

The new model was developed by determining whether human noroviruses can infect "humanized" mice, this is mice containing human immune cells. These mice are widely used for study of the human immunodeficiency virus (HIV), a virus which can only infect human cells.

As a control researchers also included the same mice without human immune cells. In the study, both groups of mice were infected by human norovirus.

Additional studies determined that the immunodeficient background of this particular mouse strain is important in permitting human norovirus infection and identified macrophages, a vital immune cell in the body, as the cell type infected by the virus.

Very few particles of the virus can lead to infection. Estimates are as few as 18 particles can cause gastroenteritis (inflammation of the stomach and intestines) and lead to diarrhea, vomiting and stomach pain. In the U.S. norovirus causes approximately 21 million cases of acute gastroenteritis a year, and 800 deaths.

"Most people can cope with the symptoms, but deaths are more likely among the elderly mainly because of dehydration," Wobus says.

Only the common cold is more widespread than the norovirus, which can remain on surfaces for weeks, ready to cause more infections. Because it lacks a lipid envelope, norovirus is not susceptible to common disinfectants and alcohol-based sanitizers.

The economic impact of these infections is staggering with an economic cost for norovirus associated food-borne outbreaks alone of $5.8 billion in the U.S.

There is no vaccine for preventing norovirus infection and no drug to treat it. But the Centers for Disease Control and Prevention offers some tips for prevention, including handwashing with soap and water, washing fruits and vegetables properly and cleaning and disinfecting surfaces, and if you are sick not preparing food or caring for others.


'/>"/>

Contact: Shantell M. Kirkendoll
smkirk@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Study links mental illness to early death in people with epilepsy
2. Study: EBV Mononucleosis Risk Increased by Smoking and Family Size; polyDNA Recommends Gene-Eden-VIR Against the Latent EBV
3. Overnights away from home affect childrens attachments, U.Va. study shows
4. DrugRisk Update: New Study Warns of Pradaxa Dangers as Lawsuits Increase
5. Attorneys at Michael D. Ponce & Associates React to a Study Concluding 40 That Nearly Percent of Designated Drivers Consume Alcohol
6. Study finds boys more likely to receive HPV vaccine when their mothers receive preventive care
7. CU study illuminates mortality differences between nondrinkers and light drinkers
8. Weight loss drug helps curb cocaine addictions, Penn study finds
9. Electronic health records help fight vaccine-preventable diseases, Columbia Nursing study finds
10. Study identifies a simple way to reduce healthcare costs
11. Study demonstrates link between reclassification of cannabis and cannabis psychosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on his ... the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family ... hospital’s 30th heart transplant recipient. , “He was playing at home, when we got ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving back to ... fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. AlignLife ... children of the world. , In exchange for generous donations, customers will receive a ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers Delightful Holiday ... Up To 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 , ... Delightful Deals on Botox® and Juvederm® just in time for the holiday party ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, ... medicines company, announced today that it entered into ... RNA-based therapeutics for the treatment of NASH and ... therapeutic delivery platform LUNAR™ and UNA Oligomer chemistry. ... "Given Takeda,s long-standing commitment to and expertise in ...
(Date:12/6/2016)... 2016  Regulus Therapeutics Inc. (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... R&D day, held in New York ... anti-miR targeting microRNA-27 (miR-27) for the treatment of ... anti-miR targeting microRNA-17 (miR-17) for the treatment of ...
(Date:12/6/2016)... A new study released today by the ... the 340B Drug Pricing Program will continue to expand at ... expected to exceed $23 billion in total purchases at the ... current Medicare Part B drug reimbursement purchases over the next ... on analysis of data on total drug purchases through 340B ...
Breaking Medicine Technology: